Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

Immunic

Domain Not Resolving

Microsoft Exchange Online

Office 365 Mail

Person Schema

Sr. Director Medical Science

John Carlins

Head of Intellectual Property

Christian G.

Healthcare

Katja Blazej

Business Management

Lourdes Iglesias

Senior Manager Quality Management

Olga Rudneva

Executive Assistant / Office Manager

Tamara Tahlov

Daniel Vitt

Duane Nash

Gigi Mehrotra

Senior ELAD Specialist

Iris Quimby

Jörg Neermann

Hella Kohlhof

Chief Scientific Officer

CEO, President and Director

Andreas Muehler

Co-Founder & Chief Medical Officer

Executive Chairman

Jason Tardio

President and Chief Operating Officer

Darius-Jean Namdjou

Head of Regulatory Affairs & Pharmacovigilance

Medical Companies With Less Than $10M in Revenue (Top 10K)

Biotechnology Companies With More Than 10 Employees (Top 10K)

Biotechnology Public Companies With More Than 10 Employees

Companies that Went Public in 2019

Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Biotechnology Value Fund

Post-IPO Equity - Immunic Therapeutics

German Federal Ministry of Education and Research

Grant - Immunic Therapeutics

Fund+

Omega Funds

Series A - Immunic Therapeutics

LSP BioVentures

EQT Life Sciences

LifeCare Partners

New York

United States

North America

Immunic Therapeutics

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic Therapeutics on LinkedIn: #immunic #imux #vidofludimus #imu838 #emphasis #clinicaltrials…

Immunic Therapeutics on LinkedIn: #eurohealthleaders #biotechleadership #healthcareinnovation #biotechnology…

New US patent likely for vidofludimus calcium at MS trial doses

Immunic, Inc. Announces Proposed Public Offering of Common Stock

IMUX Stock Price Increases Over 5% Pre-Market: Why It Happened

An investigational oral drug in development for treating multiple sclerosis and other chronic inflammatory and autoimmune diseases, combining neuroprotective, anti-inflammatory, and anti-viral effects.

A small molecule targeting Sirtuin 6 to restore intestinal barrier function and regenerate bowel epithelium, potentially applicable in gastrointestinal diseases like celiac disease.

A next-generation molecule in preclinical testing aimed at addressing gastrointestinal diseases.

United Kingdom

Europe

Philippines

Asia

India

Poland

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 17, 2024 6:41 AM	da2799e0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 17, 2024 6:41 AM	46fd72b1
crunchbase trigger	general	Nov 18, 2024 2:12 PM	9be65ccc
crunchbase profile	general	Nov 19, 2024 1:38 AM	646f1979
li profile	general
translate crunchbase fundingrounds	general	Nov 19, 2024 2:03 AM	08e76ad7
peers	general	Oct 17, 2024 6:41 AM	aff038fc
news basic	general	Oct 17, 2024 6:41 AM	cc256175
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:IMUX

Immunic

Last Close

1.11

22/11 21:00

Market Cap

115.30M

Beta: -

Volume Today

779.33K

Avg: -